Search
Akari Therapeutics PLC
AKTXAdd to Watchlist
8.625USD
+0.235+2.80%
Close 10-07 16:00（ET）
16.79MMarket Cap
LossP/E TTM
Akari Therapeutics PLC (AKTX) Stock Price Target & Forecast
Analyst Rating
Based on 4 analysts giving stock ratings to Akari Therapeutics PLC in the past month.
Buy
1 Strong Buy
3 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
29.125USD+234.00%
AKTX Analyst Recommendation Trends
In the current month, AKTX has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AKTX average Analyst price target in the last month is 29.125.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
1
1
1
1
1
1
1
1
3
3
3
2
2
2
3
3
0
0
0
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
4
4
4
4
4
4
4
Financial Forecasting
Based on analysts' estimates, AKTX EPS is projected to reach -2.090 in FY2026Q3, following reported EPS of -2.400 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-1.50
-1.38
-1.28
-2.09
-0.92
Actual
-0.12
-384.00
-2.40
--
--
Surprise
+92.00%
-27793.39%
-87.50%
--
--
FAQs
What is Akari Therapeutics PLC's price target?
Analysts forecast that Akari Therapeutics PLC's price target is USD 5.00, with the highest forecast at USD 7.00 and the lowest forecast at USD 1.60.
How have Akari Therapeutics PLCAKTX's recent earnings per share performed?
The market expectation was USD -2.40, while Akari Therapeutics PLCAKTX's earnings per share (EPS) for the previous quarter was USD -384.00. EPS for the next quarter is expected at USD -2.09.
What is the analyst rating for Akari Therapeutics PLC?
Based on the ratings of Akari Therapeutics PLC's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.